// App-Quantinova.ai

: ETV6/RUNX1 FUSION GENE ABROGATION DECREASE THE ONCOGENIC POTENCIAL OF TUMORS CELLS IN A PRECLINICAL MODEL OF ACUTE LYMPHOBLASTIC LEUKEMIA

Researchers

Presenter

  • Adrian Montao

Principal Investigators

  • Jose Luis Ordez

  • Vernica Alonso-Prez

  • Ana Marn-Qulez

  • Claudia Prez-Carretero

  • Roco Benito

  • Ignacio Garca-Tun

  • Jess Mara Hernndez-Rivas

Medical Centers

  • IBSAL, IBMCC, Universidad de Salamanca-CSIC, Cancer Research Center; Salamanca,Salamanca,Spain

  • Unidad de Diagnóstico Molecular y Celular del Cáncer, Centro de Investigación del Cáncer-IBMCC (USAL-CSIC),,Salamanca,Spain

  • IBSAL, IBMCC, Universidad de Salamanca-CSIC, Cancer Research Center; Salamanca,Salamanca,Spain

  • Unidad de Diagnóstico Molecular y Celular del Cáncer, Centro de Investigación del Cáncer-IBMCC (USAL-CSIC),,Salamanca,Spain

  • Department of Medicine, Universidad de Salamanca, Spain.and Department of Hematology, Hospital Universitario de Salamanca; Salamanca; Spain.,Salamanca,Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • ETV6-RUNX1

  • Interleukin-2

Drug/Treatment

  • Prednisolone

  • Copanlisib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved